A Phase 1 interventional study of Alisertib in Advanced Solid Tumors and Lymphomas, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in Singapore. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.
Among the 26 studies in Lymphoma by Takeda, this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2012, is one of 12 in phase 1, and was the 8th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in India
Ages 18+
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 6 · Phase 3 2 · Phase 4 3
First in 1997; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 36 across the 23 interventional studies, 1,000 across the 3 observational. Of the 24 that completed or were terminated, 17 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Lymphoma by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine the safety profile, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to characterize the pharmacokinetic (PK) profile of alisertib twice daily (BID) dosing for 7 days in East Asian participants with advanced solid tumors or lymphomas. The secondary objective was to describe any antitumor activity that may have been observed with alisertib treatment.
The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have advanced solid tumors or lymphomas for which standard curative or life-prolonging treatment did not exist or was no longer effective or tolerable. This study evaluated the safety and pharmacokinetic (PK) profile, and maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of alisertib, as well as any antitumor activity.
The study enrolled 36 patients. Participants were assigned to one of the two treatment groups and received:
This multi-center trial is conducted in East Asia. The overall time to participate in this study was 24 months, unless it was determined that a participant would derive benefit from continued therapy beyond 24 months. Participants made multiple visits to the clinic, and were contacted up to a maximum of 30 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 30 mg enteric-coated tablets (ECT), orally, twice a day (BID) for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 16 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
Drug: Alisertib
Alisertib 40 mg ECT, orally, BID for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 7 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
Drug: Alisertib
Alisertib enteric-coated tablets
Also known as: MLN8237
Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
MTD was defined as highest dose at which \<2 participants experienced a dose-limiting toxicity (DLT). DLT was defined as any of the following events considered possibly related to therapy with alisertib by the investigator: 1. Grade 4 neutropenia (absolute neutrophil count \<500 cells/mm\^3) for \>7 days; 2. Grade 4 neutropenia with fever (oral or ear temperature ≥38.5°C); 3. Grade 4 thrombocytopenia (platelets \<25,000/mm\^3) for \>7 days; 4. Platelet count \<10,000 cells/mm\^3; 5. ≥Grade 3 thrombocytopenia with clinically significant bleeding; 6. Delay in initiation of subsequent cycle by \>7 days due to treatment-related toxicity; 7. ≥Grade 3 nonhematological toxicity except following: a. ≥Grade 3 nausea and/or emesis in the absence of optimal antiemetic therapy; b. ≥Grade 3 diarrhea in the absence of optimal supportive therapy; c. Grade 3 fatigue lasting \<1 week; d. Other Grade 3 nonhematological toxicity that can be safely and reliably controlled to ≤Grade 2 with appropriate treatment.
Time frame: Treatment Cycle 1
Number of Participants With Adverse Events and Serious Adverse Events
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: First dose to 30 days past last dose (Up to 12.1 Months)
Number of Participants With Abnormal Clinical Laboratory Values Reported as Adverse Events
Laboratory AEs in the following system organ classes (SOCs) are reported: blood and lymphatic system disorders, investigations, and metabolism and nutrition disorders. An abnormal laboratory value was assessed as an AE if that value lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from baseline. A treatment¬-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: First dose to 30 days past last dose (Up to 12.1 Months)
Number of Participants With Clinically Significant Changes in Vital Signs Reported as Adverse Events
Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.
Time frame: First dose to 30 days past last dose (Up to 12.1 Months)
Cmax: Maximum Observed Concentration for Alisertib
Time frame: Cycle 1 Days 1 and 7 predose and at multiple time points (up to 12 hours) postdose
Tmax: Time to First Occurrence of Cmax for Alisertib
Time frame: Cycle 1 Days 1 and 7 predose and at multiple time points (up to 12 hours) postdose
AUCτ: Area Under the Concentration-Time Curve From Time 0 to End of Dosing Interval (τ) for Alisertib
Time frame: Cycle 1 Days 1 and 7 predose and at multiple time points (up to 12 hours) postdose
Dose Normalized AUCτ: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib
Dose normalized AUCτ was obtained using AUCτ divided by alisertib dose in milligrams.
Time frame: Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose
T1/2: Terminal Half-Life for Alisertib
Time frame: Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose
Rac: Accumulation Ratio for Alisertib
Time frame: Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose
PTR: Peak Trough Ratio During a Dosing Interval, at Steady State for Alisertib
Time frame: Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose
CLss/F: Apparent Clearance After Extravascular Administration, at Steady State, Calculated Using AUCτ for Alisertib
Time frame: Cycle 1 Day 7 predose and at multiple time points (up to 12 hours) postdose
Best Overall Response Rate Based on Investigator Assessment
Best overall response rate is defined as the percentage of participants with complete response (CR) and/or partial response (PR) as assessed by the Investigator using Lymphoma International Working Group (IWG) Criteria or Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT, PET or MRI. IWG criteria for CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites. RECIST response criteria is defined as: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.
Time frame: Baseline and every 2 cycles for up to 24 months or until progressive disease
Duration of Response
DOR is defined as the time from the date of first documentation of a CR response to the date of first documentation of PD according to IWG criteria or RECIST criteria 1.1. IWG PD is defined as PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir. RECIST PD is defined as unequivocal progression of existing non-target lesions.
Time frame: First documented response until disease progression; approximately 12 months
Concentrations of Relevant Tumor Markers
Time frame: Cycle 1, Day 1; at end of Cycle 2 and every 2 cycles thereafter; and at end treatment; approximately 12 months
Participants took part in the study at 8 investigative sites in Singapore, Taiwan, Hong Kong, and South Korea from 06 February 2012 to 08 October 2013.
| Milestone | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| Started | 30 | 6 |
| Completed | 30 | 6 |
| Not completed | 0 | 0 |
MTD was defined as highest dose at which \<2 participants experienced a dose-limiting toxicity (DLT). DLT was defined as any of the following events considered possibly related to therapy with alisertib by the investigator: 1. Grade 4 neutropenia (absolute neutrophil count \<500 cells/mm\^3) for \>7 days; 2. Grade 4 neutropenia with fever (oral or ear temperature ≥38.5°C); 3. Grade 4 thrombocytopenia (platelets \<25,000/mm\^3) for \>7 days; 4. Platelet count \<10,000 cells/mm\^3; 5. ≥Grade 3 thrombocytopenia with clinically significant bleeding; 6. Delay in initiation of subsequent cycle by \>7 days due to treatment-related toxicity; 7. ≥Grade 3 nonhematological toxicity except following: a. ≥Grade 3 nausea and/or emesis in the absence of optimal antiemetic therapy; b. ≥Grade 3 diarrhea in the absence of optimal supportive therapy; c. Grade 3 fatigue lasting \<1 week; d. Other Grade 3 nonhematological toxicity that can be safely and reliably controlled to ≤Grade 2 with appropriate treatment.
| mg | Alisertib 30 mg or 40 mg |
|---|---|
| Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | 30 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| Participants | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| AE | 30 | 6 |
| SAE | 15 | 4 |
Laboratory AEs in the following system organ classes (SOCs) are reported: blood and lymphatic system disorders, investigations, and metabolism and nutrition disorders. An abnormal laboratory value was assessed as an AE if that value lead to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from baseline. A treatment¬-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| Neutropenia | 19 | 5 |
| Anaemia | 9 | 4 |
| Thrombocytopenia | 6 | 1 |
| Febrile neutropenia | 4 | 1 |
| Leukopenia | 2 | 2 |
| White blood cell count decreased | 7 | 0 |
| Aspartate aminotransferase increased | 6 | 0 |
| Neutrophil count decreased | 4 | 0 |
| Alanine aminotransferase increased | 4 | 0 |
| Platelet count decreased | 3 | 0 |
| Blood bilirubin increased | 2 | 0 |
| Haemoglobin decreased | 1 | 0 |
| Blood creatinine increased | 0 | 1 |
| Urine output decreased | 1 | 0 |
| Hypokalaemia | 4 | 3 |
| Hypercalcaemia | 0 | 1 |
| Hyponatraemia | 1 | 0 |
Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.
| Participants | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| Hypertension | 1 | 0 |
| Hypotension | 1 | 0 |
| Bradycardia | 1 | 0 |
| Pyrexia | 8 | 1 |
| nM | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| Day 1 | 1442.5 ± 534.80 | 1871.7 ± 429.62 |
| Day 7 | 3000.0 ± 1329.38 | 3686.7 ± 885.45 |
| hr | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| Day 1 | 3.0 (2 to 8) | 2.0 (2 to 3) |
| Day 7 | 2.9 (1 to 6) | 2.0 (1 to 3) |
| nM*hr | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| Day 1 | 9549.0 ± 4119.30 | 11811.7 ± 2845.76 |
| Day 7 | 24377.9 ± 13261.61 | 30683.3 ± 9575.68 |
Dose normalized AUCτ was obtained using AUCτ divided by alisertib dose in milligrams.
| nM*hr/mg | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| Dose Normalized AUCτ: Area Under the Concentration-Time Curve From Time 0 to Time t for Alisertib | 812.9 ± 441.90 | 766.8 ± 238.88 |
| hr | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| T1/2: Terminal Half-Life for Alisertib | 16.750 ± 8.1710 | 14.795 ± 4.5715 |
| ratio | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| Rac: Accumulation Ratio for Alisertib | 2.830 ± 1.2955 | 2.690 ± 1.0638 |
| ratio | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| PTR: Peak Trough Ratio During a Dosing Interval, at Steady State for Alisertib | 2.254 ± 0.6458 | 2.207 ± 0.3946 |
| L/hr | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| CLss/F: Apparent Clearance After Extravascular Administration, at Steady State, Calculated Using AUCτ for Alisertib | 2.9357 ± 1.37091 | 2.8083 ± 1.20259 |
Best overall response rate is defined as the percentage of participants with complete response (CR) and/or partial response (PR) as assessed by the Investigator using Lymphoma International Working Group (IWG) Criteria or Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 for target lesions and assessed by CT, PET or MRI. IWG criteria for CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites. RECIST response criteria is defined as: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.
| percentage of participants | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| CR | 0 | 0 |
| PR | 3 | 0 |
DOR is defined as the time from the date of first documentation of a CR response to the date of first documentation of PD according to IWG criteria or RECIST criteria 1.1. IWG PD is defined as PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir. RECIST PD is defined as unequivocal progression of existing non-target lesions.
| days | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| Duration of Response | 169 (169 to 169) | — |
No measurements were reported for this outcome.
Collected over First dose to 30 days past last dose (Up to 12.1 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alisertib 30 mg | — | 15/30 (50%) | 30/30 (100%) |
| Alisertib 40 mg | — | 4/6 (66.7%) | 6/6 (100%) |
| Event | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/30 | 3/6 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/30 | 1/6 |
| AnaemiaBlood and lymphatic system disorders | 1/30 | 1/6 |
| LeukopeniaBlood and lymphatic system disorders | 1/30 | 1/6 |
| StomatitisGastrointestinal disorders | 3/30 | 1/6 |
| Subcutaneous abscessInfections and infestations | 0/30 | 1/6 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 1/6 |
| HypokalaemiaMetabolism and nutrition disorders | 0/30 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 2/30 | 0/6 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/30 | 0/6 |
| Event | Alisertib 30 mg | Alisertib 40 mg |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 19/30 | 3/6 |
| DiarrhoeaGastrointestinal disorders | 17/30 | 3/6 |
| StomatitisGastrointestinal disorders | 16/30 | 2/6 |
| AnaemiaBlood and lymphatic system disorders | 8/30 | 3/6 |
| AlopeciaSkin and subcutaneous tissue disorders | 14/30 | 3/6 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 3/30 | 3/6 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 3/30 | 3/6 |
| HypokalaemiaMetabolism and nutrition disorders | 4/30 | 3/6 |
| LethargyNervous system disorders | 0/30 | 3/6 |
| FatigueGeneral disorders | 12/30 | 2/6 |
Safety Population is defined as all participants who received at least one dose of alisertib.
| Age, Continuous(years) | Alisertib 30 mg | Alisertib 40 mg | Total |
|---|---|---|---|
| Mean | 57.2 ± 9.52 | 50.7 ± 18.25 | 56.1 ± 11.35 |
| Sex: Female, Male(Participants) | Alisertib 30 mg | Alisertib 40 mg | Total |
|---|---|---|---|
| Female | 11 | 2 | 13 |
| Male | 19 | 4 | 23 |
| Race/Ethnicity, Customized(Participants) | Alisertib 30 mg | Alisertib 40 mg | Total |
|---|---|---|---|
| Asian (Chinese) | 17 | 5 | 22 |
| Asian (Korean) | 13 | 0 | 13 |
| Malay | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Alisertib 30 mg | Alisertib 40 mg | Total |
|---|---|---|---|
| Not Hispanic or Latino | 30 | 6 | 36 |
| Region of Enrollment(Participants) | Alisertib 30 mg | Alisertib 40 mg | Total |
|---|---|---|---|
| Singapore | 4 | 6 | 10 |
| Taiwan | 8 | 0 | 8 |
| Hong Kong | 5 | 0 | 5 |
| Korea, Republic of | 13 | 0 | 13 |
| Height(cm) | Alisertib 30 mg | Alisertib 40 mg | Total |
|---|---|---|---|
| Mean | 162.5 ± 6.84 | 161.9 ± 6.61 | 162.4 ± 6.71 |
| Weight(kg) | Alisertib 30 mg | Alisertib 40 mg | Total |
|---|---|---|---|
| Mean | 57.78 ± 9.255 | 62.30 ± 11.714 | 58.53 ± 9.669 |
| Body Surface Area (BSA)(m^2) | Alisertib 30 mg | Alisertib 40 mg | Total |
|---|---|---|---|
| Mean | 1.611 ± 0.1487 | 1.667 ± 0.1613 | 1.620 ± 0.1499 |
Ran from Feb 2012 to primary completion in Oct 2013, 20 months.
Results were first posted in Mar 2019, 5 years 5 months after primary completion.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 20 months is below that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →